Similarly, in Asia, SGLT2 inhibitor treatment is an evidence-based therapeutic regimen for primary prevention of hospitalizations caused by HF and secondary prevention of cardiovascular events in patients with T2DM.18 This evidence concerns the gene SLC5A2 and hydrops fetalis.